Tech Company Financing Transactions
Neoantigenics Funding Round
On 3/31/2015, Neoantigenics raised $2.7 million in funding from CIT GAP Fund and private investors.
Transaction Overview
Company Name
Announced On
3/31/2015
Transaction Type
Venture Equity
Amount
$2,656,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1000 Research Park Blvd. 103
Charlottesville, VA 22911
USA
Charlottesville, VA 22911
USA
Phone
Website
Email Address
Overview
Neoantigenics, Inc. is a Virginia Corporation focused on developing oncology theranostics (therapeutic plus diagnostic) products, founded on the novel science around oocyte (egg)-associated cancer neoantigens discovered at the University of Virginia.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Brian Pollok
Chief Financial Officer
Ed Leary
Chief Scientific Officer
John Herr
Browse more venture capital transactions:
Prev: 3/31/2015: CommercialTribe venture capital transaction
Next: 3/31/2015: Fitbit venture capital transaction
Share this article
News on VC Transactions
We do our best to report on funding rounds that are announced publicly. VC investment data records reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs